Literature DB >> 12523456

Erythromycin accelerates gastric emptying in a dose-response manner in healthy subjects.

Michel A Boivin1, Michael C Carey, Howard Levy.   

Abstract

STUDY
OBJECTIVES: To evaluate whether a dose-response curve exists for erythromycin, determine the lowest effective dose of erythromycin needed to improve gastric motility, and compare erythromycin's effectiveness with that of metoclopramide in improving gastric emptying.
DESIGN: Randomized, crossover, multiintervention trial.
SETTING: Inpatient clinical research center.
SUBJECTS: Ten healthy volunteers (four men, six women) from the general population. INTERVENTION: On each study day, the subjects were infused with erythromycin 0.75 mg/kg, 1.5 mg/kg, or 3.0 mg/kg; metoclopramide 10 mg; or placebo, in random order. Subjects then drank Ensure 200 ml mixed with acetaminophen 1.5 g. Gastric emptying was estimated by comparing the area under the curve after 60 minutes for acetaminophen absorption using four timed blood draws.
MEASUREMENTS AND MAIN RESULTS: Erythromycin increased gastric emptying in a dose-response manner. Erythromycin 3.0 mg/kg and metoclopramide 10 mg were associated with statistically significant increases in liquid gastric emptying compared with placebo. During infusion, nausea and stomach cramping were associated with the 3.0-mg/kg dose of erythromycin; drowsiness was associated with metoclopramide.
CONCLUSION: In patients requiring intravenous erythromycin for gastric motility, the 3.0-mg/kg dose seems the most effective, with a reasonable side effect profile.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12523456     DOI: 10.1592/phco.23.1.5.31919

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  8 in total

1.  Noninvasive Magnetogastrography Detects Erythromycin-Induced Effects on the Gastric Slow Wave.

Authors:  Suseela Somarajan; Nicole D Muszynski; Dilovan Hawrami; Joseph D Olson; Leo K Cheng; Leonard A Bradshaw
Journal:  IEEE Trans Biomed Eng       Date:  2018-05-17       Impact factor: 4.538

2.  The pharmacodynamics, safety and pharmacokinetics of single doses of the motilin agonist, camicinal, in type 1 diabetes mellitus with slow gastric emptying.

Authors:  Per M Hellström; Jan Tack; Lakshmi Vasist Johnson; Kimberley Hacquoil; Matthew E Barton; Duncan B Richards; David H Alpers; Gareth J Sanger; George E Dukes
Journal:  Br J Pharmacol       Date:  2016-04-13       Impact factor: 8.739

3.  Differences between the abilities of tegaserod and motilin receptor agonists to stimulate gastric motility in vitro.

Authors:  E M Jarvie; V J North Laidler; S Corcoran; A Bassil; G J Sanger
Journal:  Br J Pharmacol       Date:  2007-01-08       Impact factor: 8.739

4.  Premedication with erythromycin improves endoscopic visualization of the gastric mucosa in patients with subtotal gastrectomy: a prospective, randomized, controlled trial.

Authors:  Byoung Yeon Jun; Myung-Gyu Choi; Jong Yul Lee; Myong-Ki Baeg; Sung Jin Moon; Chul-Hyun Lim; Jin Su Kim; Yu Kyung Cho; In Seok Lee; Sang Woo Kim; Kyu Yong Choi
Journal:  Surg Endosc       Date:  2014-01-01       Impact factor: 4.584

5.  Effects of rhubarb on isolated gastric muscle strips of guinea pigs.

Authors:  Mei Yu; Ya-Li Luo; Jun-Wei Zheng; Yong-Hui Ding; Wei Li; Tian-Zhen Zheng; Song-Yi Qu
Journal:  World J Gastroenterol       Date:  2005-05-07       Impact factor: 5.742

6.  Regional- and agonist-dependent facilitation of human neurogastrointestinal functions by motilin receptor agonists.

Authors:  J Broad; S Mukherjee; M Samadi; J E Martin; G E Dukes; G J Sanger
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

7.  The hungry stomach: physiology, disease, and drug development opportunities.

Authors:  Gareth J Sanger; Per M Hellström; Erik Näslund
Journal:  Front Pharmacol       Date:  2011-02-18       Impact factor: 5.810

8.  Motilin: towards a new understanding of the gastrointestinal neuropharmacology and therapeutic use of motilin receptor agonists.

Authors:  G J Sanger; Y Wang; A Hobson; J Broad
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.